(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 17 June 2004 (17.06.2004)

PCT

(10) International Publication Number WO 2004/050101 A2

(51) International Patent Classification7: A61P 31/14

A61K 33/04,

(21) International Application Number:

PCT/EP2003/013514

(22) International Filing Date: 1 December 2003 (01.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

US

(30) Priority Data: 102 55 861.2 60/430,367

103 05 138.4

60/446,246

29 November 2002 (29.11.2002) DE 3 December 2002 (03.12.2002) 7 February 2003 (07.02.2003) DE

11 February 2003 (11.02.2003)

(71) Applicant (for all designated States except US): AXXIMA PHARMACEUTICALS AG [DE/DE]; Max-Lebsche-Platz 32, 81377 Munich (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HERGET, Thomas [DE/DE]; Georgenstrasse 29, 82152 Planegg (DE). KLEBL, Bert [DE/DE]; Imhoffstrasse 16, 82294 Günzlhofen (DE).


Agents: LEIDESCHER, Thomas et al.; Zimmermann & Partner, P.O. Box 330 920, 80069 Munich (DE).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

[Continued on next page]



the prophylaxis and/or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D3 and retinoids, like all trans retinoic acid and salts thereof, C1 - C alkyl amide of all trans retinoic acid and salts thereof, C1 - C10 alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C1 - C10 alkyl arnide of 9-cis retinoic acid and salts thereof, C1 - C10 alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2 (5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthalenyl-1-propenyl) benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphtalenyl) carboxamido] benzoic acid (AM-580), N-(4-hydroxyphenyl) retinamide (4-HPR), and 6-[3-(1- adamantyl) -4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).